Safety

As our mission statement confirms, product safety is the principal concern of Daval International Limited.

Medical practitioners prescribing this unlicensed product under the various national Special Access Schemes are reminded of the fact that most countries operate a Side Effect and Adverse Events Reporting System. In the United Kingdom, the MHRA operates a "Yellow Card" system, which enables swift reporting of adverse effects.

Back to AIMSPRO

    5th Nov 2009
AIMSPRO receives US orphan-drug designation for ALS
    29th Sep 2009
Ceremben Permit Approved
    22nd Jul 2009
Patent granted by the OAPI
Design by